Similar articles

• The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor.

  Edwards J, Bartlett JM. Edwards J, et al. BJU Int. 2005 Jun;95(9):1320-6. doi: 10.1111/j.1464-410X.2005.05526.x. BJU Int. 2005. PMID: 15892825 Review. No abstract available.
• Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.

  Ramberg H, Eide T, Krobert KA, Levy FO, Dizeyi N, Bjartell AS, Abrahamsson PA, Taskén KA. Ramberg H, et al. Prostate. 2008 Jul 1;68(10):1133-42. doi: 10.1002/pros.20778. Prostate. 2008. PMID: 18454446
• Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo.

  Landriscina M, Bagalà C, Piscazzi A, Schinzari G, Quirino M, Fabiano A, Bianchetti S, Cassano A, Sica G, Barone C. Landriscina M, et al. Prostate. 2009 May 15;69(7):744-54. doi: 10.1002/pros.20923. Prostate. 2009. PMID: 19152342
• Cell cycle regulator cdk2ap1 inhibits prostate cancer cell growth and modifies androgen-responsive pathway function.

  Zolochevska O, Figueiredo ML. Zolochevska O, et al. Prostate. 2009 Oct 1;69(14):1586-97. doi: 10.1002/pros.21007. Prostate. 2009. PMID: 19585490
• Androgen receptor signaling in prostate cancer.

  Culig Z, Santer FR. Culig Z, et al. Cancer Metastasis Rev. 2014 Sep;33(2-3):413-27. doi: 10.1007/s10555-013-9474-0. Cancer Metastasis Rev. 2014. PMID: 24384911 Review.